Epidermolysis Bullosa Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Epidermolysis Bullosa pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Sample copy is available at
Companies Involved in Epidermolysis Bullosa Development are Abeona Therapeutics Inc, Almirall SA, Amryt Pharma plc, Anterogen Co Ltd, Berg LLC, CSL Ltd, Exicure Inc, Fibrocell Science Inc, GlaxoSmithKline Plc, Immusoft Corp, InMed Pharmaceuticals Inc, Karus Therapeutics Ltd.
Drug Profiles discussed in this research are Epidermolysis Bullosa, AC-203, ADP-31415, allantoin, ALLO-ASC, Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex etc.
The Epidermolysis Bullosa pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 8, 2, 9 and 6 respectively.
Scope of this report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa. The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epidermolysis Bullosa therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Epidermolysis Bullosa therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa.
- This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa. Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.